PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
Czasopismo
2011 | 6 | 1 | 123-130
Tytuł artykułu

Prognostic factors for positive immune thrombocytopenic purpura outcome after laparoscopic splenectomy

Treść / Zawartość
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
Laparoscopic splenectomy is considered as a second step treatment for ITP patients. The purpose of this study was to determine efficiency of laparoscopic splenectomy for ITP patients and to identify the independent prognostic factors that may predict the positive outcome. Two hundred and thirty nine patient medical records were analyzed retrospectively. The special questionnaire, which included present platelet count, the steroid usage and its dosage, was sent to all patients. The complete response (CR) was defined, when the platelet count was above 130 × 109 /L. The 239 adult patients with a median age of 51.3 (16–93 years) were included in this cohort. The median follow up period was 75 months. 49 patients, who relapsed after steroid treatment, underwent laparoscopic splenectomy. The short term postoperative CR was 71.4% after laparoscopic splenectomy compared to 38.1% in non-splenectomized patients (p < 0.000). The long term CR was 79.5 % in patients after splenectomy compared to 47.4% in non-splenectomized patients (p < 0.018). After univaried analysis three clinical variables were found to be significantly related to splenectomy outcome: disease duration (p<0.007), preoperative platelet count (p<0.049) and platelet count on the third postoperative day (p<0.000). Multiple logistic regression analysis demonstrated, that only platelet count on the 3rd postoperative day > 129 × 109 /L; RR=53.3 95% (CI, 1.888–1517.98) was significant predictor for long-term positive ITP outcome after laparoscopic splenectomy. Splenectomy is effective treatment for ITP. Platelet count > 129 × 109/L on the third postoperative day is the significant predictor of positive long-term outcome after laparoscopic splenectomy.
Słowa kluczowe
Wydawca
Czasopismo
Rocznik
Tom
6
Numer
1
Strony
123-130
Opis fizyczny
Daty
wydano
2011-02-01
online
2010-12-16
Twórcy
  • Clinic of Surgery of Kaunas University of Medicine, A. Mickeviciaus 9, Kaunas, 44307, Lithuania , minkiud@yahoo.com
  • Clinic of Surgery of Kaunas University of Medicine, A. Mickeviciaus 9, Kaunas, 44307, Lithuania
  • Clinic of Hematology of Kaunas University of Medicine, A. Mickeviciaus 9, Kaunas, 44307, Lithuania
  • Clinic of Hematology of Kaunas University of Medicine, A. Mickeviciaus 9, Kaunas, 44307, Lithuania
  • Clinic of Hematology of Kaunas University of Medicine, A. Mickeviciaus 9, Kaunas, 44307, Lithuania
  • Clinic of Intensive Care of Kaunas University of Medicine, A. Mickeviciaus 9, Kaunas, 44307, Lithuania
Bibliografia
  • [1] Imbach P, Kühne T, Signer E Historical aspects and present knowledge of idiopathic thrombocytopenic purpura. (2002) Br J Haematol 119:894–900 http://dx.doi.org/10.1046/j.1365-2141.2002.03755.x[Crossref]
  • [2] McMillan R Therapy for adults with refractory chronic immune thrombocytopenic purpura. (1997) Ann Int Med 126(4):307–314 [Crossref]
  • [3] Stevens W, Koene H, Zwaginga JJ, Vreugdenhil G. Chronic idiopathic thrombocytopenic purpura: present strategy, guidelines and new insights. (2006) Neth J Med. Nov 64(10):356–363
  • [4] Delaitre B, Maignien B. Splenectomy by the laparoscopic approach. (1991) Report of a case. Presse Med 20:2263
  • [5] Delaitre B, Maignien B. Laparoscopic splenectomy - Technical aspects. (1992) Surg Endosc 6:305–308 http://dx.doi.org/10.1007/BF02498866[Crossref]
  • [6] Consensus statement Laparoscopic splenectomy: the clinical practice guidelines of the European Association for Endoscopic Surgery (EAES). (2008) Surg Endosc 22:821–848
  • [7] Aksnes J, Abdelnoor M, Mathisen O Risk factors associated with mortality and morbidity after elective splenectomy. (1995) Eur J Surg 161: 253–258
  • [8] Stasi R, Stipa E, Masi M, et al Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. (1995) American Journal of Medicine 98:436–4442 http://dx.doi.org/10.1016/S0002-9343(99)80342-8[Crossref]
  • [9] McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. (1997) Ann Intern Med 136:307–314
  • [10] George JN, El-Harake MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. (1994) N Engl J Med 331:1207–1211 http://dx.doi.org/10.1056/NEJM199411033311807[Crossref]
  • [11] Stasi R, Stipa E, Masi M, et al Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. (1995) American Journal of Medicine 98:436–442 http://dx.doi.org/10.1016/S0002-9343(99)80342-8[Crossref]
  • [12] Bourgeois E, Caulier MT, Delarozee C, et al Long-term follow-up of chronic autoimmune thrombocytopenic purpura refractory to splenectomy: a prospective analysis. (2003) British Journal of Haematology 120:1079–1088 http://dx.doi.org/10.1046/j.1365-2141.2003.04211.x[Crossref]
  • [13] Leung AYH, Chim CS, Kwong YL, et al Clinicopathologic and prognostic features of chronic idiopathic thrombocytopenic purpura in adult Chinese patients: an analysis of 220 cases. (2001) Annals of Hematology 80:384–386 http://dx.doi.org/10.1007/s002770100306[Crossref]
  • [14] Rodeghiero F. Idiopathic thrombocytopenic purpura: an old disease revisited in the era of evidence-based medicine. (2003) Haematologica 88:1081–1087
  • [15] Cheng Y, Wong RS, Soo YO, et al Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. (2003) N Engl J Med 349:831–836 http://dx.doi.org/10.1056/NEJMoa030254[Crossref]
  • [16] Alpdogan O, Budak-AldoGan T, Ratip S, et al Efficacy of high-dose methylprednisolone as a first-line therapy in adult patients with idiopathic thrombocytopenic purpura. (1998) Br J Haemat 103:1961–1963 http://dx.doi.org/10.1046/j.1365-2141.1998.01096.x[Crossref]
  • [17] Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. (2004) Mayo Clin Proc 79:504–522 http://dx.doi.org/10.4065/79.4.504[Crossref]
  • [18] Colovic M, Dimitrijevic M, Sonnenberg C, et al Clinical efficacy and safety of a novel intravenous immunoglobulin preparation in adult chronic ITP. (2003) Hematol J 4:358–362 http://dx.doi.org/10.1038/sj.thj.6200303[Crossref]
  • [19] George JN, Woolf SH, Raskob GE, et al Idiopathic thrombocytopenic purpura: a guideline developed by explicit methods for the American Society of Hematology. (1996) Blood 88:3–40.
  • [20] Giagounidis AA, Anhuf J, Schneider P, et al Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. (2002) Eur J Haematol 69:95–100. http://dx.doi.org/10.1034/j.1600-0609.2002.02686.x[Crossref]
  • [21] Zaja F, Vianelli N, Sperotto A, et al The B-cell compartment as the selective target for the treatment of immune thrombopenias. (2003) Haematology 88:538–546
  • [22] Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune (2003) 78:1340–1346
  • [23] Cooper N, Stasi R, Cunningham-Rundles S, et al The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. (2004) Br J Haematol 125:232–239 http://dx.doi.org/10.1111/j.1365-2141.2004.04889.x[Crossref]
  • [24] Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. (2001) Blood 98:952–957 http://dx.doi.org/10.1182/blood.V98.4.952[Crossref]
  • [25] Braendstrup P, Bjerrum OW, Nielsen OJ, et al Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. (2005) Am J Hematol 78:275–280 http://dx.doi.org/10.1002/ajh.20276[Crossref]
  • [26] Medeot M, Zaja F, Vianelli N, et al Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: longterm follow-up results. (2008) Eur J Haematol 81(3):165–169 http://dx.doi.org/10.1111/j.1600-0609.2008.01100.x[Crossref]
  • [27] Patel V, Mihatov N, Cooper N, et al Long term follow-up of patients with immune thrombocytopenic purpura whose initial response to rituximab lasted a minimum of 1 year. (2006) Blood (suppl):abstract 479
  • [28] Kuter DJ, Bussel JB, Senecal FM, et al Evaluation of AMG 531 in nonsplenectomized patients with chronic immune thrombocytopenic purpura in a randomized placebo-controlled phase 3 study. (2007)
  • [29] Bussel JB, Kuter DJ, de Wolf JThM, et al Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 2-year update. (2007) Blood 110:174a, abstract number 568
  • [30] Blanchette V, Freedman J, Garvey B. Management of chronic immune thrombocytopenic purpura in children and adults. (1998) Semin Hematol 35(suppl. 1):36–51
  • [31] George JN, Kojouri K, Perdue JJ, Vesely SK Management of patients with chronic, refractory idiopathic thrombocytopenic purpura. (2000) Semin Hematol 37(3):290–298 http://dx.doi.org/10.1016/S0037-1963(00)90107-0[Crossref]
  • [32] Maloisel F, Andres E, Zimmer J, et al Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. (2004) Am J Med 116(9):590–594 http://dx.doi.org/10.1016/j.amjmed.2003.12.024[Crossref]
  • [33] Andrès E, Zimmer J, Noel E, et al Idiopathic thrombocytopenic purpura: a retrospective analysis in 139 patients of the influence of age on the response to corticosteroids, splenectomy and danazol. (2003) Drugs Aging 20:841–846 http://dx.doi.org/10.2165/00002512-200320110-00005[Crossref]
  • [34] Ahn YS, Rocha R, Mylvaganam R, et al Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women. (1989) Ann Int Med 111:723–729 [Crossref]
  • [35] Kim SW, Rice L, McCarthy JJ. Efficacy of danazol with autoimmune thrombocytopenia. (1997) Clin Appl Thrombosis/Hemostasis 3:251–255 http://dx.doi.org/10.1177/107602969700300406[Crossref]
  • [36] Rice L. Danazol, idiopathic thrombocytopenic purpura, and thrombopoietin. (2004) Am J Med 117(12):972–973 http://dx.doi.org/10.1016/j.amjmed.2004.10.003[Crossref]
  • [37] Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. (2000) Arch Intern Med 160:1630–1638 http://dx.doi.org/10.1001/archinte.160.11.1630[Crossref]
  • [38] Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy forrefractory autoimmune thrombocytopenic purpura. (1995) Blood 85:351–358
  • [39] Kappers-Klunne MC, van het Veer B. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. (2001) Br J Haematol 114:212–215 http://dx.doi.org/10.1046/j.1365-2141.2001.02893.x[Crossref]
  • [40] Perrota S, Amendola G, Locatelli F, et al Treatment with short-term, high-dose cyclosporine A in children with refractory chronic idiopathic thrombocytopenic purpura. (2003) Br J Haematol 121:143–147 http://dx.doi.org/10.1046/j.1365-2141.2003.04254.x[Crossref]
  • [41] British Committee for Standards in Haemotology Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. (2003) Br J Haematol 120:574–596
  • [42] George JN, Woolf SH, Raskob GE, et al Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of hematology. (1996) Blood 88:3–40
  • [43] Kiarash Kjouri, Sara K. Vesely, Deirdra R. Terrell et al Splenectomy for adults with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. (2004) Blood 104:2623–2632 http://dx.doi.org/10.1182/blood-2004-03-1168[Crossref]
  • [44] Stanton CJ. Laparoscopic splenectomy for idiopathic thrombocytopenic purpura (ITP): a five-year experience. (1999) Surg Endosc 13: 1083–1086 http://dx.doi.org/10.1007/s004649901178[Crossref]
  • [45] Fabris F, Tassan T, Ramon R. et al Age as the major predictive factor of long-term response to splenectomy in immune thrombocytopenic purpura. (2001) Br J Haematol 112: 637–640 http://dx.doi.org/10.1046/j.1365-2141.2001.02615.x[Crossref]
  • [46] Kumar S, Diehn FE, Gertz MA, Tefferi A. Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses. (2002) Ann Hematol 81(6):312–319 http://dx.doi.org/10.1007/s00277-002-0461-8[Crossref]
  • [47] Duperier T, Brody F, Felsher J, Walsh M, Rosen M, Ponsky J. Predictive factors for successful laparoscopic splenectomy in patients with immune thrombocytopenic purpura. (2004) Arch Surg 139: 61–66 http://dx.doi.org/10.1001/archsurg.139.1.61[Crossref]
  • [48] Katkhouda N, Grant SW, Mavor E, et al Predictors of response after laparoscopic splenectomy for immune thrombocytopenic purpura. (2001) Surg Endosc 15:484–488 http://dx.doi.org/10.1007/s004640000355[Crossref]
  • [49] Schiavotto C, Rodeghiero F. Twenty years experience with treatment of idiopathic thrombocytopenic purpura in a single department: results in 490 cases. (1993) Haematologica 78: 22–28
  • [50] Radaelli F, Faccini P, Goldaniga M, et al Factors predicting response to splenectomy in adult patients with idiopathic thrombocytopenic purpura. (2000) Haematologica 85:1040–1044
  • [51] Ruivard M, Caulier MT, Vantelon JM. The response to high-dose intravenous immunoglobulin or steroids is not predictive of outcome after splenectomy in adults with autoimmune thrombocytopenic purpura. (1999) Br J Haematol 105:1130–1132 http://dx.doi.org/10.1046/j.1365-2141.1999.01464.x[Crossref]
  • [52] Wilde RC, Ellis LD, Cooper WM. Splenectomy for chronic idiopathic thrombocytopenic purpura. (1967) Arch Surg 95:344–350 [Crossref]
  • [53] den Ottolander GJ, Gratama JW, deKoning J et al Long-term follow-up study of 168 patients with immune thrombocytopenia. (1984) Scand J Haematol 32:101–110 http://dx.doi.org/10.1111/j.1600-0609.1984.tb00684.x[Crossref]
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.-psjd-doi-10_2478_s11536-010-0063-0
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.